Novel thioredoxin reductase inhibitor butaselen inhibits tumorigenesis by down-regulating programmed death-ligand 1 expression.
- Author:
Qiao ZOU
1
;
Yi-Fan CHEN
1
;
Xiao-Qing ZHENG
1
;
Suo-Fu YE
1
;
Bin-Yuan XU
1
;
Yu-Xi LIU
1
;
Hui-Hui ZENG
1
Author Information
- Publication Type:Journal Article
- Keywords: Butaselen; Signal transducer and activator of transcription 3 (STAT3); Programmed death-ligand 1 (PD-L1); Immunity; Thioredoxin reductase
- MeSH: Animals; Antineoplastic Agents/pharmacology*; B7-H1 Antigen/antagonists & inhibitors*; Benzene Derivatives/therapeutic use*; CD8-Positive T-Lymphocytes/drug effects*; Hep G2 Cells; Humans; Liver Neoplasms/pathology*; Male; Mice; Organoselenium Compounds/therapeutic use*; STAT3 Transcription Factor/physiology*; Thioredoxin-Disulfide Reductase/antagonists & inhibitors*; Tumor Burden/drug effects*
- From: Journal of Zhejiang University. Science. B 2018;19(9):689-698
- CountryChina
- Language:English
- Abstract: The thioredoxin system plays a role in a variety of physiological functions, including cell growth, differentiation, apoptosis, tumorigenesis, and immunity. We previously confirmed that butaselen (BS), a novel thioredoxin reductase inhibitor, can inhibit the growth of various human cancer cell lines, yet the underlying mechanism remains elusive. In this study, we investigated the anti-tumor effect of BS in vivo through regulating the immune system of KM mice. We found that BS inhibits tumor proliferation by promoting the activation of splenic lymphocytes in mice. BS can elevate the percentage of CD4-CD8+ T lymphocytes and the secretion of downstream cytokines in mice via down-regulating the expression of programmed death-ligand 1 (PD-L1) on the tumor cells' surface in vivo. Further study in HepG2 and BEL-7402 cells showed that decrease of PD-L1 level after BS treatment was achieved by inhibiting signal transducer and activator of transcription 3 (STAT3) phosphorylation. Taken together, our results suggest that BS has a role in promoting the immune response by reducing PD-L1 expression via the STAT3 pathway, and subsequently suppresses tumorigenesis.
